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Abstract
Background: Large vessel vasculitis is a rare disorder usually occurring in the context of the autoimmune conditions
of giant cell arteritis and Takayasu’s arteritis. Case reports have described large vessel vasculitis occurring in individuals
with myelodysplastic syndrome, preceding transformation to acute myeloid leukemia.
Case presentation: A 56-year-old Afghanistan-born woman presented with fever, a tender left carotid artery, and raised
inflammatory markers. Computed tomography revealed thickening of the wall of her left carotid artery. Her symptoms
resolved spontaneously; however, they recurred weeks later on the contralateral side, along with abdominal pain after
eating. Further imaging with computed tomography and positron emission tomography demonstrated resolution of her
left carotid artery abnormality, but new wall thickening and inflammation in her right carotid artery, abdominal aorta, and
superior mesenteric artery. She was diagnosed as having large vessel vasculitis, which resolved with corticosteroids and
methotrexate. Five months later, she developed acute myeloid leukemia. She had no known history of myelodysplastic
syndrome at the time of diagnosis with vasculitis.
Conclusions: Large vessel vasculitis in older individuals presenting with atypical clinical features, such as a migratory
pattern of affected vessels, vessel wall tenderness, and marked systemic inflammation, should prompt a search for
underlying myelodysplasia. Clinicians should be vigilant for progression to acute myeloid leukemia.
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Background
Large vessel vasculitis is a rare condition characterized by
inflammation within the walls of the aorta and its major
branches. It can occur in a range of autoimmune disor-
ders, including Takayasu’s arteritis (TA) and giant cell
arteritis (GCA), and typically requires treatment with high
doses of corticosteroids and other immunosuppressive
agents. In the literature, there have been case reports of
large vessel vasculitis occurring in individuals with myelo-
dysplastic syndrome (MDS), some of whom have later
developed acute myeloid leukemia (AML). We describe a
patient with an atypical presentation of large vessel vascu-
litis, which was migratory in nature and accompanied by
marked systemic inflammatory features. Unlike previous
case reports, our patient did not have a prior diagnosis of
MDS, but subsequently developed AML.
Case presentation
A 56-year-old Afghanistan-born woman presented to our
hospital with a 2-week history of constant left-sided neck
pain, associated fevers (38.0 °C), and rigors. Her past med-
ical history included mild asthma and osteoarthritis. A
physical examination revealed exquisite tenderness over
the anterior triangle of her left neck. Laboratory studies
showed a white cell count of 4.1 × 109 cells/L (reference
range 3.9 to 11.1), hemoglobin 112 g/L (115 to 165), mean
corpuscular volume (MCV) 96 fL (82 to 98), C-reactive
protein (CRP) 109 mg/L (≤3), with normal electrolytes
and liver function tests. Computed tomography (CT) of
her neck (Fig. 1) revealed wall thickening of her left dis-
tal common carotid artery with hazing of the adjacent
fat. Autoimmune serology, including anti-nuclear anti-
bodies, anti-neutrophil cytoplasmic antibodies, anti-
bodies to extractable nuclear antigens, double stranded-
deoxyribonucleic acid (DNA) antibodies, rheumatoid
factor, and antibodies to cyclic citrullinated peptide,
were negative. These results were helpful in excluding a
systemic small vessel vasculitis. Her serum complement
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levels were normal, and a left temporal artery biopsy was
negative. Her neck pain and fevers resolved spontaneously
without corticosteroids or other immunosuppression and
she was discharged home on day 6. She presented 17 days
later with fever (38.0 °C) and abdominal pain 20 to 30 mi-
nutes after eating. A CT of her abdomen (Fig. 2) revealed
mild upper abdominal periaortic stranding with mural
thickening, similar in appearance to her left common ca-
rotid artery from the original CT scan of her neck. During
the next 24 to 48 hours, she developed new right-sided
neck pain, contralateral to her pain on initial presentation.
A CTangiogram revealed improvement in her left common
carotid artery thickening, interval development of new right
common carotid artery thickening, and hazing around her
upper abdominal aorta, coeliac axis, and superior mesen-
teric arteries. A positron emission tomography (PET) scan
(Fig. 3) demonstrated diffuse, intense fluorodeoxyglucose
(FDG) uptake of her right common carotid artery, abdom-
inal aorta, and superior mesenteric artery, consistent with a
large vessel vasculitis, which had presented with a systemic
inflammatory response, carotidynia, and mesenteric angina.
She was treated with methylprednisolone (500 mg daily
for 3 days) administered intravenously with immediate
resolution of her abdominal and neck pain and fevers. She
was subsequently commenced on methotrexate 15 mg/
week administered orally and prednisone 50 mg/day. She
remained well over the following 5 months, with continu-
ation of methotrexate, and her prednisone dose was
gradually reduced to 15 mg/day.
Five months later, she reported fatigue and persistent
cough despite multiple courses of antibiotics. Blood tests
revealed neutropenia with >20 % blasts on peripheral
blood film. A subsequent bone marrow aspirate (Fig. 4)
demonstrated a markedly hypercellular marrow with 69
% blasts, which by flow cytometry were identified as an
abnormal population of myeloid cells expressing CD117,
CD13, CD33, human leukocyte antigen-antigen D
related (HLA-DR), CD123, lacking CD34, with aberrant
CD4 expression, consistent with AML. Molecular
studies showed a FLT3-internal tandem duplication
(ITD) mutation, which characterizes more aggressive
disease and frequent relapses [1]. She received induction
chemotherapy with cytarabine and idarubicin but a
month later a bone marrow aspirate demonstrated
residual blasts (9 %) consistent with persistent AML.
She received re-induction chemotherapy with cytarabine
and idarubicin, and then further re-induction with
fludarabine, cytarabine, and idarubicin. Despite initial
morphological remission, her AML relapsed 3 months
later. She had many infective complications, including
febrile neutropenia and Clostridium difficile colitis, but
her large vessel vasculitis did not recur. Due to a rapidly
rising blast count and refractory disease, she was palli-
ated and died 8 months after her diagnosis of AML.
Discussion
We present a case of large vessel vasculitis with atypical
features, including a migratory involvement of affected
vessels and marked systemic inflammatory features, with
subsequent progression to AML.
Large vessel vasculitis associated with MDS has rarely
been described [2]. In some cases, the diagnoses of MDS
and large vessel vasculitis are made simultaneously, and in
others, the MDS has been pre-existing. Our patient did
not have a previous diagnosis of MDS before the develop-
ment of vasculitis, and on presentation, had only minim-
ally reduced hemoglobin (112 g/L). Over the following
weeks, her peripheral blood neutrophil count fluctuated
between normal and mildly reduced (1.4 to 3.4 × 109 cells/
L), as did her monocyte count (0.5 to 1.8 × 109 cells/L);
Fig. 1 Computed tomography of the neck on initial presentation
revealing wall thickening of the left distal common carotid artery
with hazing of the adjacent fat (red arrow)
Fig. 2 Computed tomography of the abdomen on second
presentation revealing mild upper abdominal periaortic stranding
with mural thickening of the aorta (red arrow), similar in appearance
to the left common carotid artery from the original computed
tomography of her neck (Fig. 1)
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however, her platelet count remained normal. With high
dose glucocorticoids, her neutrophil count rose to 6.0 ×
109 cells/L; however, the absence of a steroid-induced
neutrophilia may also suggest a degree of myelodysplasia.
The mild monocytosis, although not specific in the con-
text of inflammation, may have been significant, given that
her subsequent AML blasts aberrantly expressed CD4,
which is normally expressed on monocytes.
Large vessel vasculitis can occur in autoimmune disor-
ders, including extracranial GCA and TA. Marked sys-
temic inflammation may be a feature of TA, however this
disorder classically affects individuals younger than 50
years of age [3, 4]. GCA, more frequently seen in older
individuals, typically involves smaller vessels such as the
temporal arteries, but can also affect the aorta and its
major branches. The few reported cases of MDS-
associated large vessel vasculitis presented in a similar
manner to our patient: at an age >50 years, with acute
inflammation, including tender vessels and a highly raised
CRP [2, 5, 6], exceeding the median CRP of 52 mg/L in
patients with temporal artery biopsy-proven GCA [7].
In one review, five of eight patients with MDS-
associated large vessel vasculitis developed AML, often
refractory, usually within a year of presentation with vas-
culitis [2]. The timing of large vessel vasculitis preceding
AML, and the unusual clinical features of acute inflamma-
tion with vessel wall tenderness and highly elevated
inflammatory markers, suggest that the vasculitis in these
patients may be a paraneoplastic phenomenon. The cyto-
penias in some forms of MDS may be immune mediated
[8], with activated T cells inducing cytokine-mediated
apoptosis of myeloid stem cells via tumor necrosis factor
(TNF) and interferon gamma [5, 9]. Dysregulated immune
mechanisms may thus be involved in the pathogenesis of
MDS [10]. The association between MDS and auto-
immune phenomena, such as arthritis, vasculitis, and
connective tissue diseases, is well recognized in the litera-
ture [11, 12]; however MDS-associated vasculitis more
commonly affects small caliber vessels [11, 13, 14].
Although the vasculitis in our patient responded
promptly to glucocorticoids, the subsequent emergence
of AML raises the possibility that immunosuppression
impaired the cytotoxic anti-tumor response, and thus
unmasked the AML. The majority of cases of patients
reported with both large vessel vasculitis and MDS,
however, received no steroid-sparing agent, yet several
still progressed to AML [2]. In light of the poor progno-
sis when given corticosteroids, it is important to
Fig. 3 Positron emission tomography scan demonstrating diffuse, intense fluorodeoxyglucose uptake of the right common carotid artery (red
arrow), abdominal aorta (blue arrow), and superior mesenteric artery (green arrow)
Fig. 4 Bone marrow aspirate demonstrating features of acute
myeloid leukemia including myeloblasts (red arrows) >20 %
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recognize the high risk of progression to AML in these
individuals. Consideration may be given to simultaneous
treatment for MDS, including azacitidine or even high
intensity chemotherapy followed by allogeneic stem cell
transplantation in selected patients with good perform-
ance status. A recent multicenter study confirmed that
treatment with azacitidine in patients with both MDS
and a systemic inflammatory or autoimmune disease
appeared to have a positive effect on their inflammatory
condition [15]; however, whether this treatment would
reduce progression to AML in individuals with concur-
rent large vessel vasculitis is undetermined.
Conclusions
In summary, we present a 56-year-old woman with a
large vessel vasculitis with migratory features, vessel wall
tenderness, and marked systemic inflammation, who
subsequently developed AML. Large vessel vasculitis
with atypical clinical features in older individuals should
prompt a search for underlying myelodysplasia, and vigi-
lance for progression to AML.
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